“The recent decision by the United States Department of Justice to support rescheduling of marijuana from a schedule I to a schedule III controlled substance, is a move we believe will ultimately lead to increased use of cannabis containing products among US households. This potentially includes edible products that are often the cause of unintentional cannabis poisoning in children. Our decision to prioritize the development of an intravenous treatment for children is driven by multiple factors. Our prior discussions with United States Food and Drug Administration have highlighted the need for an alternative formulation of selonabant for treating younger patients. There is increasing recognition among clinicians that this is a growing unmet medical need in a vulnerable population where there are no approved treatments. Our belief is that the path to approval for an oral treatment for adult ACI may be facilitated by an initial approval in the pediatric population,” commented Richie Cunningham, CEO of Anebulo. “Anebulo is uniquely positioned to provide a rapid and clinically impactful solution for Emergency Departments to treat children suffering from unintentional cannabis poisoning,” Cunningham continued. “Research has shown children are much more sensitive to the toxic effects of cannabis. Key factors such as smaller body size, reduced ability to metabolize delta-9-tetrahydrocannabinol, and the fact that younger children have an underdeveloped endocannabinoid system with more cannabinoid receptor type 1 receptors in the brain all contribute to a much greater risk to children.”